Glenmark Pharmaceuticals U.S. > News

News

Press Releases

Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.

Glenmark Pharmaceuticals receives ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC)

April 29, 2024

Glenmark Pharma receives ANDA approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg

November 7, 2023

Glenmark Pharmaceuticals receives ANDA approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg

October 17, 2023

Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%

August 25, 2023

Glenmark Pharmaceuticals receives ANDA approval for Saxagliptin Tablets, 2.5 mg and 5 mg

August 13, 2023

News

Search Result :-

Is an investigational new drug that has not been approved for commercial distribution in the United States.

April 29, 2024
Glenmark Pharmaceuticals receives ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC)

November 7, 2023
Glenmark Pharma receives ANDA approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg

October 17, 2023
Glenmark Pharmaceuticals receives ANDA approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg

August 25, 2023
Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%

August 13, 2023
Glenmark Pharmaceuticals receives ANDA approval for Saxagliptin Tablets, 2.5 mg and 5 mg

US Media Contact

For media inquiries only, please contact Corporate Communications.
uscomms@glenmarkpharma.com

Investor Relations

For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.

POTASSIUM CHLORIDE EXTENDED RELEASE CAPSULES 750mg RECALL REIMBURSEMENT POLICY

Over-the-counter (OTC)

ACCESSIBLE PRODUCTS

Who We Are

Injectables

OUR GROWING LINE